These studies indicated that autologous T cells directed to the LMP antigen could induce sustained complete remission (CR) in NKTCL patients, demonstrating that EBV proteins could act as effective targets for NKTCL immunotherapy. The gene discussed is PDLIM7; the disease is extranodal nasal NK/T cell lymphoma.